NCT05893381View on ClinicalTrials.gov

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

April 30, 2032

Conditions
Prostate Cancer
Interventions
DRUG

[177Lu]Lu-PSMA I&T

The radiopharmaceutical 177Lu-PSMA-I\&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.

RADIATION

Stereotactic Radiotherapy

Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,

Trial Locations (2)

47014

RECRUITING

UO Medicina Nucleare, IRCCS IRST, Meldola

47521

RECRUITING

UO Medicina Nucleare, AUSL della Romagna, Cesena

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER